礼来近期发布2025Q3业绩,第三季度营收176.01亿美元,同比增长54%。综合前两个季度的业绩来看,礼来在今年前九个月的总营收为458.87亿美元(+46%)。替尔泊肽和阿贝西利是礼来制药业务营收增长的主力,在前三季度分别创收248.37亿美元(+125%)和41.18亿美元(+10%)。此外,礼来GLP-1产品和诺和诺德GLP-1产品的美国市场处方量占比差距在Q3进一步扩大(57.9% vs...
Source Link礼来近期发布2025Q3业绩,第三季度营收176.01亿美元,同比增长54%。综合前两个季度的业绩来看,礼来在今年前九个月的总营收为458.87亿美元(+46%)。替尔泊肽和阿贝西利是礼来制药业务营收增长的主力,在前三季度分别创收248.37亿美元(+125%)和41.18亿美元(+10%)。此外,礼来GLP-1产品和诺和诺德GLP-1产品的美国市场处方量占比差距在Q3进一步扩大(57.9% vs...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.